Domino’s reported network sales down 2% and EBIT up 1% in 1H26.  The company is pursuing cost savings and lower discounting aggressively. However, so far the drop in same store sales seems larger than the gross margin gain for franchisees. We expect SSSg to decline in FY26e and return to very modest growth in FY27e as the company focuses more on gross margins. A good portion of targeted cost savings will be passed onto franchisees. Even so they account for less than half the required lift in franchisee EBITDA. Domino’s is taking decisive action to restore profitability but we expect the stock to be range bound until the new CEO starts by August 2026.

Harvey Norman reported 15% EBITDA growth in 1H26. Sales growth was solid in both the key markets of Australia and New Zealand and profit margins expanded with better cost control. Harvey Norman’s sales trends are likely to slow in Australia and NZ over the next 12 months, but we expect it to be a mild slowdown. The improved inventory position for franchisees bodes well for margin expansion in 2H26e.

Viva reported FY25 EBITDA down 6%, but 2H25 EBITDA up 33%. The turnaround in fortunes in Convenience is encouraging, albeit higher fuel margins in 2H25 may not be sustained. Cost savings from FY25 and improving shop gross margins help lift our FY26e Convenience EBITDA to $246 million. We can see a path to $336 million by FY28e, or 71% higher than FY25. However, executing on a supply chain transition and OTR store conversions will be necessary. We see asset sales of $150-200 million as sufficient to bring down leverage from 3.0x in FY25 to 2.0x in FY27e.

Lovisa reported 1H26 EBIT on an underlying basis (ex-Jewells) of $109 million, up 20%. Underlying gross margin improved 50bp to 82.9% and store growth of 64 stores took the store count to 1,095 stores. Total sales in the first six weeks of 2H26e grew 21.5%. Our sales forecasts lift on store count. We lift gross margin expectation but also increase both operating costs and depreciation. The result was impacted by losses in Jewells, Lovisa’s new brand. Jewells may develop into a long-term opportunity but could distract management from course correcting Australian division performance and managing the global Lovisa rollout.

Nick Scali delivered 1H26 EBIT of $68.5 million, up 25%. NPAT of $41 million was ahead of both guidance and Visible Alpha consensus. The group gross margin increase of 318bp, surprised to the upside and resulted in 65.4% for the half. Nick Scali’s ANZ trading update for January like-for-like written sales orders at 3.1% highlighted a deterioration in momentum. We have lowered our sales forecasts but lifted gross margin expectations.

Lovisa will hold its Annual General Meeting on 21 November. In the past Lovisa has provided an update on LFL sales and store numbers. Visible Alpha consensus has 1H26e LFL sales of 5.4%, implying a modest slowing from the first eight weeks of trade. We expect to see a LFL number above 5.3% supported by the US segment where price rises and competitor disruptions have benefitted sales. Our concern is that the LFL sales growth fades in FY27e to 2% as the US benefits are cycled and domestic competitive pressures grow.

Nick Scali’s AGM guidance was a miss to Visible Alpha consensus for 1H26e. However, the trading update showed strong sales momentum in ANZ and a clear path to breakeven in the UK. The ANZ guidance implies either flat gross margins or elevated costs. Sales momentum will need to continue in a highly promotional environment to offset cost growth. The UK is tracking well to reach breakeven and could exit 2H26e with a small profit. The promotional environment in ANZ presents a risk to gross margins.

Sigma Warehouse reported its 1Q26 sales at its AGM. Chemist Warehouse like-for-like sales were up 14.7% for the quarter, an acceleration on FY25 trends. The company highlighted elevated sales of weight-loss drugs like Ozempic as a big contributor. We estimate the contribution is anywhere from 3%-5% of the LFL growth. We expect LFL sales to settle back at 11% in 2Q26e and 9.0% in 2H26e.

dusk reported FY25 sales of $137 million, up 8.7%. Like-for-like (LFL) sales growth of 7.1% meant a 2H25 LFL sales growth of 3.6%. The trading update for the first eight weeks saw total sales down 1.5%, cycling 16% growth in same period last year. We reference the two-year stack in our forecast for LFL sales growth of 4.2% for FY26e. With limited store openings and growth in LFL sales we forecast FY26e revenue forecasts of $144 million, up 4.9%.

Sigma reported FY25 network sales growth for Chemist Warehouse of 14% and EBIT at $903 million, up 47%. The company reported a continuation of double-digit like-for-like sales growth with a lift in profit margins for the underlying Chemist Warehouse business. We forecast EBIT growth of 22% in FY26e ahead of revenue growth of 15%. Margins will be helped by penetration of Wagner private label, operating leverage from strong comp sales and the increasing synergies over the next four years.